Strada Healthcare Launches COVID-19 Antibody Test to Measure Vaccine Effectiveness
February 11, 2021
As the COVID-19 vaccine becomes available to the public, immunity monitoring is playing an important role in determining vaccine effectiveness. Strada Healthcare is pleased to offer Roche’s Elecsys® Anti-SARS-CoV-2 S test to help Omaha and Lincoln area residents detect antibody production after infection and vaccination.
The test is available at Strada’s Omaha (11810 Nicholas St.) and Lincoln (4545 S. 86th St.) facilities. The cost is $125, and results are available within 72 hours.
“Most antibody tests on the market today only detect antibody production after someone has been infected with the virus, but many people want to know if they have developed antibodies after receiving the vaccine as well,” said Lisa Fisher, Director of Operations at Strada Healthcare. “We’re pleased to offer a test that recognizes both.”
Strada partnered with Boston Heart Diagnostics to provide the new antibody test, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood) test can be used to measure the level of antibodies in people who have been exposed to the SARS-CoV-2 virus, including those who have received Pfizer, Moderna and AstraZeneca vaccines.
For optimal results, individuals are encouraged to wait at least three weeks following an infection or a vaccination before taking the antibody test in order to identify potential exposure and immunity. These antibodies increase significantly within three weeks after the first injection of either the Moderna and Pfizer mRNA vaccines, and the values are especially high after the second dose, according to Boston Heart Diagnostics.
For more information or to schedule an antibody test, visit stradahealthcare.com/testing.